REDWOOD CITY, Calif.--(BUSINESS WIRE)--May 31, 2017--
Dextera Surgical Inc. (Nasdaq:DXTR), a company developing and
commercializing the MicroCutter 5/80™ stapler, today announced that its
MicroCutter 5/80™ was highlighted in three sessions during the 25thEuropean Conference on General Thoracic Surgery (ESTS), held in
Innsbruck, AustriaMay 28-31, 2017.
On Monday, May 29, Dr. Marco Nardini presented a video case study
entitled “Microlobectomy: A novel video-assisted thoracic surgical
(VATS) approach.” The presentation demonstrated the procedure-enabling
aspects of the MicroCutter on large and small pulmonary arteries and
veins. On Wednesday, May 31, Dr. Joel Dunning presented “VATS: The
journey to less invasiveness,” highlighting faster discharge with the
Microlobectomy technique, where twenty percent of patients go home one
day after surgery and an additional seventeen percent went home on day
two. Also on May 31, Mahmoud Ismail, from the Charite University
Hospital (Berlin) highlighted the MicroCutter in a session entitled,
“VATS: Technology and New Devices.”
“The interest in the MicroCutter 5/80 continues to grow, particularly as
it is highlighted by thought-leading surgeons as an important,
procedure-enabling surgical stapler,” commented Liam Burns, vice
president of worldwide sales and marketing for Dextera Surgical. “The
presentations at ESTS showcase the less invasive procedural approaches
enabled by MicroCutter as proven in Microlobectomy, and also the
excitement for using the device to enable other successful
video-assisted thoracic surgery (VATS) procedures.”
MicroCutter Indication Information
The MicroCutter 5/80 Stapler and MicroCutter 30 Reloads are manufactured
and cleared for use in the United States for transection and resection
in multiple open or minimally invasive urologic, thoracic and pediatric
surgical procedures, as well as application for transection, resection
and/or creation of anastomoses in the small and large intestine, and the
transection of the appendix. The MicroCutter 5/80 may be used with both
MicroCutter 30 White Reloads in vascular/thin tissue and MicroCutter 30
Blue Reloads for standard tissue.
About Dextera Surgical
Dextera Surgical (Nasdaq:DXTR) designs and manufactures proprietary
stapling devices for minimally invasive surgical procedures. In the
U.S., surgical staplers are routinely used in more than one million
minimally invasive laparoscopic, video-assisted or robotic-assisted
surgical procedures annually.
Dextera Surgical also markets the only automated anastomosis devices for
coronary artery bypass graft (CABG) surgery on the market today: the
C-Port® Distal Anastomosis Systems and PAS-Port® Proximal Anastomosis
System. These products, sold by Dextera Surgical under the Cardica brand
name, have demonstrated long-term reliable clinical performance for more
than a decade.
The statement in this press release regarding interest in Dextera
Surgical’s MicroCutter 5/80 continuing to grow is a "forward-looking
statement." There are a number of important factors that could cause
Dextera Surgical’s results to differ materially from those indicated by
these forward-looking statements, including the risks detailed from time
to time in Dextera Surgical’s reports filed with the U.S. Securities and
Exchange Commission, including its Quarterly Report on Form 10-Q for the
quarter ended March 31, 2017, under the caption “Risk Factors.” Dextera
Surgical expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to this forward-looking statement. You
are encouraged to read Dextera Surgical’s reports filed with the U.S.
Securities and Exchange Commission, available at www.sec.gov.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170531005443/en/
Source: Dextera Surgical Inc.
Dextera Surgical Inc.
Bob Newell, 650-331-7133
Finance and Chief Financial Officer